276
Participants
Start Date
June 13, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
AAV2-hAQP1 Concentration 1
Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
AAV2-hAQP1 Concentration 2
Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
Placebo
Administration of diluent via Stensen's duct to each parotid gland
AAV2-hAQP1 Concentration 3
Administration of concentration 3 of AAV2-hAQP1 via Stensen's duct to each parotid gland
AAV2-hAQP1 Concentration 4
Administration of concentration 4 of AAV2-hAQP1 via Stensen's duct to each parotid gland
RECRUITING
Erie County Medical Center, Buffalo
RECRUITING
Alleghany General Hospital, Pittsburgh
RECRUITING
Penn State, Hershey
RECRUITING
Johns Hopkins Hospital, Baltimore
RECRUITING
UNC-Chapel Hill, Chapel Hill
RECRUITING
Atrium Health, Charlotte
RECRUITING
Miami Cancer Institute at Baptist Health South Florida, Miami
RECRUITING
Henry Ford Health, Detroit
RECRUITING
University of Iowa, Iowa City
RECRUITING
Northwestern Memorial Hospital, Chicago
RECRUITING
University of Missouri, Columbia
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
Houston Methodist, Houston
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
City of Hope, Duarte
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Shirley and Jim Fielding Northeast Cancer Centre - Health Sciences North, Greater Sudbury
RECRUITING
Hopital Fleurimont, CIUSSS de l'Estrie-CHUS, Québec
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
Addenbrooke's Hospital, Cambridge
RECRUITING
CIUSSS-MCQ (Trois-Rivières, QC), Trois-Rivières
RECRUITING
Ninewells Hospital & Medical School, Dundee
RECRUITING
Western General, London
RECRUITING
Guys Hospital, London
RECRUITING
Nottingham University Hospitals NHS Trust, Nottingham
Lead Sponsor
MeiraGTx, LLC
INDUSTRY